---
title: Detecting BMS-986094 Cardiotoxicity using Chronic Multiplatform Assay
description: Read our poster. Chronic Multiplatform Assay to Detect BMS-986094 Cardiotoxicity in iPSC-Derived Human Cardiomyocytes. Contact Evotec to learn more!
image: https://news.cyprotex.com/hubfs/Sciencepool/Sciencepool%20images/Shutterstock%20images/shutterstock_1257335041-cellular-green-01-science-pool.jpg
---

[![Cyprotex | The Leading ADME-Tox Specialist](https://news.cyprotex.com/hs-fs/hubfs/cyprotex%20logo.png?width=224&height=62&name=cyprotex%20logo.png "Cyprotex | The Leading ADME-Tox Specialist")](https://www.cyprotex.com/)

# Science Pool

# Detecting BMS-986094 Cardiotoxicity using Chronic Multiplatform Assay

Posted by [Evotec](https://news.cyprotex.com/sciencepool/author/evotec) on Feb 11, 2021 7:16:08 PM

BMS-986094 (INX-08189) is a prodrug of a guanosine nucleotide analogue which was developed to treat hepatitis C virus but was discontinued during clinical trials due to cardiotoxic effects.

In this poster, we focus on:

- the mechanism of BMS-986094 cardiotoxicity 
- the impact of chronic dosing over multiple time points
- evaluation of data from an MEA platform, a cardiac mitochondrial protein biogenesis assay, a calcium flux assay and a cardiac cytotoxicity assay 

Read our poster to learn more about our research!

[LEARN MORE](https://news.cyprotex.com/hubfs/Sciencepool/Posters/Cyprotex%20posters/Chronic-bms986094-cardiotoxicity-assay-sot2018.pdf)

 

 Tags: [Posters](https://news.cyprotex.com/sciencepool/tag/posters), [Toxicology & Safety](https://news.cyprotex.com/sciencepool/tag/toxicology-safety)